Target intelligence / Profile preview

SARS-CoV-2 nucleocapsid protein and SARS-CoV-2 membrane protein (N protein (Nucleocapsid protein), M protein (Membrane protein))

Target
N protein (Nucleocapsid protein), M protein (Membrane protein)
Molecular classification
structural protein, viral ribonucleoprotein component, viral envelope protein, scaffolding protein
01

Overview

The SARS-CoV-2 nucleocapsid protein (N protein) is a major internal structural component responsible for binding and packaging the viral RNA genome into ribonucleoprotein complexes, participating in virus assembly, and modulating host immune responses. It consists of N-terminal and C-terminal domains linked by a flexible, phosphorylated region and is highly immunogenic, making it a prominent target for diagnostics and antiviral strategies. The SARS-CoV-2 membrane protein (M protein) is the most abundant structural protein in the viral envelope, orchestrating virion assembly and morphology by scaffolding other viral proteins (N, S, E) and determining the shape and rigidity of the viral envelope. M protein forms dimers and oligomers, undergoes conformational changes, and interacts electrostatically with N protein and RNA; it is highly conserved and a key target for vaccine and antiviral development.

Other names
N proteinNPM proteincoronavirus nucleocapsid proteincoronavirus membrane protein
02

Mechanism of action

For N protein, inhibition of RNA binding or oligomerization can suppress viral replication. For M protein, inhibition of protein–protein interactions or oligomerization could prevent viral assembly.

03

Biological functions

RNA bindingribonucleoprotein complex formationviral genome packagingregulation of replication and transcriptionimmune modulationviral assemblyorganization of other structural proteinsdetermination of virion shapeenvelope formationinteraction scaffold for N, S, E proteins
04

Disease associations

Infection (COVID-19)
05

Safety considerations

No notable protein-specific safety concerns in terms of direct targetingdevelopment of peptide-based vaccines or inhibitors must avoid immune cross-reactivity with host proteins or adverse immunomodulatory effects
06

Interacting drugs

Small molecules targeting N protein have been investigated (e.g., RNA binding inhibitors)

2 more in the full profile.

07

Biomarkers

Both N and M proteins, as well as their peptide fragments, are widely used as diagnostic biomarkers in COVID-19 antigen tests and serology (antibody detection)

Beyond the preview

Go deeper on SARS-CoV-2 nucleocapsid protein and SARS-CoV-2 membrane protein (N protein (Nucleocapsid protein), M protein (Membrane protein)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SARS-CoV-2 nucleocapsid protein and SARS-CoV-2 membrane protein (N protein (Nucleocapsid protein), M protein (Membrane protein)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call